This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the SELECT trial and WEGOVY's (semaglutide) potential to reduce the risk of major adverse cardiovascular events (MACE) with a cardiologist

Ticker(s): NVO, LLY, AZN

Who's the expert?

Institution: Cardiac Imaging and Research Consultants

  • Board certified Cardiovascular Disease specialist with additional certifications from the American College of Cardiology, National Institutes of Health, National Board of Echocardiography.
  • Sees 5 new patients per day who have weight related cardiovascular complications.
  • Clinical and research expertise focuses on the prevention and reversal of Heart and Vascular disease, cardio metabolic disorder, the overlap of Cardiovascular Disease with weight management, kidney disease, and diabetes with expertise in lifestyle interventions.

Interview Goal
On this call, we will be digging into the results from the SELECT trial of WEGOVY (semaglutide) and discussing it's potential of reducing the risk of major adverse cardiovascular events (MACE) for obese or overweight patients with a cardiologist.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.